ABSTRACT Cell migration is a process which is essential during embryonic development, throughout adult life and in some pathological conditions. Cadherins, and more specifically the neural cell adhesion molecule N-cadherin, play an important role in migration. In embryogenesis, N-cadherin is the key molecule during gastrulation and neural crest development. N-cadherin mediated contacts activate several pathways like Rho GTPases and function in tyrosine kinase signalling (for example via the fibroblast growth factor receptor). In cancer, cadherins control the balance between suppression and promotion of invasion. E-cadherin functions as an invasion suppressor and is downregulated in most carcinomas, while N-cadherin, as an invasion promoter, is frequently upregulated. Expression of N-cadherin in epithelial cells induces changes in morphology to a fibroblastic phenotype, rendering the cells more motile and invasive. However in some cancers, like osteosarcoma, N-cadherin may behave as a tumour suppressor. N-cadherin can have multiple functions: promoting adhesion or induction of migration dependent on the cellular context.
Abbreviations used in this paper: ECM, extracellular matrix; EMT, epithelial to mesenchymal transition; MMP, matrix metalloproteinase; N-cadherin, Neural cadherin.
Migration and invasion
Cell migration is a process that is essential during embryonic development and throughout further life. In the adult, cell migration is crucial for homeostatic processes, such as effective immune responses and repair of injured tissues. To migrate, the individual cell body must modify its shape to interact with the surrounding tissue structures. The extracellular matrix (ECM) forms a substrate, as well as a barrier for the advancing cell body. Cell migration through tissues results from a continuous cycle of interdependent steps. In general, there are five steps involved in cell migration in the ECM. First comes the protrusion of the leading edge, where growing actin filaments connect to adapter proteins and push the cell membrane in an outward direction. In a second step cell-matrix interactions and focal contacts are formed. After that, surface proteases such as matrix metalloproteinases (MMP) are recruited and focal proteolysis takes place. Then the cell contracts by actomyosin activation, and finally the tail of the cell is detached from its substrate (Friedl and Wolf, 2003) .
Border cells of the Drosophila melanogaster ovary are nowadays used as a model for migration. There are three recently discovered signalling pathways that control distinct aspects of migration: a global steroid-hormone signal defines the timing of migration, a highly localised cytokine signal that activates the Janus kinase-signal transducer and activator of transcription is both necessary and sufficient to induce migration, and finally, a growth factor that is analogous to platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) contributes to guiding the cells to their destination (Montell, 2003) .
In embryonic morphogenesis two types of collective cell movement can be observed. The first one involves mass migration whereby a tissue moves in a coordinated manner. Gastrulation is an example of mass migration. In the blastocyst large groups of cells migrate collectively as sheets to form the three layers that will eventually form the embryo. Cells within these layers migrate to target locations and form various tissues and organs. The second type of movement requires loss of cell-cell contacts for the migration of individual cells or small groups of cells through the ECM, as seen in neural crest migration. Cells delaminate from the ectodermal layer and acquire migratory properties as they undergo the process of epithelial to mesenchymal transition (EMT). Another example is the migration of muscle precursor cells from the somites to the limbs (Locascio and Nieto, 2001; Horwitz and Webb, 2003) .
The failure of cells to migrate to their appropriate locations can result in developmental abnormalities and also in pathological processes, including vascular and inflammatory diseases, and tumour invasion and metastasis (Lauffenberger and Horwitz, 1996) . Aberrant cell migration may play a role in cancer. Cancer is one of the prime causes of human morbidity and mortality, and most of the cancer deaths arise from metastases. Cancer cells have defects in regulatory circuits that govern normal cell proliferation and homeostasis. A cell becomes cancerous because of essential alterations in its physiology: limitless replicative potential due to self-sufficiency in growth signals, insensitivity to growth inhibitory signals or escape from programmed cell death, induction of angiogenesis and acquisition of invasive and metastasising potential (Hanahan and Weinberg, 2000) . Of all the processes involved in tumour progression, local invasion and the formation of tumour metastases are clinically the most relevant ones, but the least well understood at the molecular level. They represent one of the great challenges in experimental cancer research.
During the progression of cancer, primary tumour cells move out, invade into adjacent tissues and travel to distant sites. Most important, these processes allow cancer cells to enter the lymphatic and blood vessels for dissemination into the circulation. Invasion is resumed when extravasation occurs in distant organs, and when the secondary tumour contributes to the metastatic cascade. Cancer cells use diverse patterns of migration. They can disseminate as individual cells or expand as solid strands, sheets, files or clusters. Leukemia, lymphoma and most sarcomas disseminate as single cells, while epithelial cells commonly use collective migration. In principle, the lower the differentiation state, the higher the tendency of the tumour to disperse via individual cells (Thiery, 2002; Friedl and Wolf, 2003) .
Similarities between the three signalling pathways described for the ovarian border cell migration, and the pathways that are deregulated in human cancer cells indicate that signals that contribute to aberrant proliferation and survival of the tumour cells, can also promote motility, and hence invasion (Montell, 2003) .
We will discuss in this review the impact of E-and N-cadherin on migration in embryogenesis and tumour invasion. Epithelial or Ecadherin plays a role in collective migration of epithelial cells. Ecadherin is also an invasion suppressor molecule, and in tumours this molecule can be downregulated in different ways (Mareel and Leroy, 2003) . Downregulation of E-cadherin is often correlated with upregulation of neural or N-cadherin, an invasion promoter molecule Li and Herlyn, 2000) . However, both the regulation of N-cadherin expression and its molecular contribution to invasion are incompletely understood.
Cadherins
In humans there are more than 80 members of the cadherin superfamily. Sequencing the genome of C. elegans and Drosophila revealed the existence of 14 and 16 different genes, respectively. Cadherins are composed of an extracellular part, that mediates calcium-dependent homophilic interactions between cadherin molecules, a transmembrane and a cytoplasmic part. The extracellular part consists of several cadherin repeats (EC) of ±110 amino-acids, which are characterised by a number of conserved amino acid sequences such as PE, LDRE, DXNDN and DXD. These motifs can bind 3 calcium ions at each interdomain boundary in a cooperative manner. Classification of cadherins into subfamilies is based on domain layout of individual cadherins, which include the number and sequence of EC repeats, and the presence of other conserved domains and sequence motifs, like tyrosine kinase and EGF domains. There are four cadherin subfamilies conserved between C. elegans, Drosophila and humans: classic cadherins, fat-like cadherins, seven-pass transmembrane cadherins and a new subfamily of cadherins that is related to Drosophila Cad 102F. Classic cadherins consist of four subgroups: vertebrate type I classic cadherins like E-, placental (P)-, N-and retinal (R)-cadherin, with an HAV sequence in the first cadherin repeat, vertebrate type II classic cadherins which have no HAV in the first repeat, for example vascular endothelial (VE)-cadherin, ascidian classic cadherins and the non-chordate classic cadherins for example D (Drosophila) E-and D (Drosophila) N-cadherin (Tepass et al., 2000) . The molecular mechanism of type I cadherin interaction has recently been unravelled. The model was proposed after elucidation of the crystal structure of the C-cadherin ectodomain: the trans-interaction is formed by a strand dimer (EC1-EC1) where association is found between the side chain of Tryptophan 2 (Trp 2 ) in one molecule and a pocket in the hydrophobic core of another molecule. The cis interaction occurs between EC1 of one molecule and EC2 of another molecule, resulting in the formation of a lattice of a supramolecular complex (Boggon et al., 2002) .
It is now known that alterations in the expression and function of cell-cell and cell-matrix adhesion molecules correlate with progression to malignancy. E-cadherin, a homotypic cell-cell adhesion molecule is expressed on most epithelial cells and is an invasion suppressor. E-cadherin expression or function is lost in most of the carcinomas. This may be by mutational inactivation of the Ecadherin gene, hypermethylation of the promoter, transcriptional repression by SIP1 or snail, loss of transactivators like RB, Myc and WT1, transactivation of other cadherins, phosphorylation of Armadillo proteins by tyrosine kinases, sterical hindrance by mucin 1 (MUC-1) or by ectodomain shedding of E-cadherin by matrix metalloproteinases (MMP) (Van Aken et al., 2001) . The proof of principle that the loss of E-cadherin is involved in the progression of tumour malignancy came from a transgenic mouse model of pancreatic β cell carcinogenesis (Rip1Tag2). In these mice, the SV40 large T antigen was expressed under the control of the rat insulin promoter, thus inducing neoplastic transformation from differentiated adenoma to invasive carcinoma selectively in the β cells of the islets of Langerhans. In these tumours E-cadherin was downregulated. Forced expression of E-cadherin in the β cell tumours resulted in an arrest in tumour development at the adenoma stage. Conversely, expression of a dominant-negative form of E-cadherin resulted in early invasion and metastasis (Perl et al., 1998) . These results show that E-cadherin suppresses tumour invasion, and that loss of E-cadherin can actively participate in the induction of tumour invasion (Cavallaro and Christofori, 2001 ).
N-cadherin
N-cadherin was first identified in 1982 (Grunwald et al., 1982) as a 130 kD molecule in the chick neural retina that was protected by calcium from proteolysis, and in 1984 A-CAM was identified (now called N-cadherin) as a molecule that was localised at the adherens junctions (Volk and Geiger, 1984) . The N-cadherin gene in mice was located on chromosome 18 (Miyatani et al., 1989) . Via Yeast Artificial Chromosome (YAC) analysis the structure of the human N-cadherin gene was determined. The entire N-cadherin gene was Fig. 1 . Schematic overview of the N-cadherin/catenin complex and the multiple proteins which associate and influence the complex. N-cadherin associates via its HBM motif with the HAV sequence of the FGFR. N-cadherin also has a HAV sequence in the first extracellular domain (EC). Activation of FGFR can lead to activation of MAPK and transcription of MMP9, inducing invasion and metastasis. In EC4, a domain is present which is responsible for Ncadherin's pro-migratory behaviour. However, in the cytoplasmic part there are also domains which can stimulate or inhibit migration. N-cadherin mediates also survival of cells via the PI3K-AKT pathway. Many molecules associate directly with the complex, such as GalNacPtase, p120 ctn , β-catenin, PTP1B, RPTPµ and Gα12, or indirectly like FER (implicated in the cadherin/catenin complex, but also in the integrin complex) and α-catenin. Many molecules can change the complex like proteases (MMP, caspase-3, PS 1) or the Robo-Abl kinase. When free cytoplasmic p120 ctn is present, it changes the morphology of the cell by blocking Rho in the GDP state or activating Rac1 and Cdc42. N-cadherin is already associated with the catenins in the ER and a microtubular kinesindriven mechanism is involved in the trafficking to the plasma membrane (Adapted from Van Aken et al., 2001 and Anastasiadis et al., 2001 ).
mapped to a 250-kb region on chromosome 18q11.2. The gene is composed of 16 exons, and homology was found not only between human and mouse, but also between N-cadherin and other cadherins (Wallis et al., 1994) . The protein exists of five extracellular cadherin repeats (EC1 to EC5), a transmembrane and a cytoplasmic part that are encoded by exons 4 to 13, 13 and 14, and 14 to 16, respectively. Eight sequence polymorphisms were identified in a Japanese population: three CCT or GCC-type trinucleotide repeat polymorphisms adjacent to the initiation codon and five other novel single-nucleotide polymorphisms in the coding region (Harada et al., 2002) . The promoter of N-cadherin does not contain CCATT or TATA boxes, but showed a high overall GC content, high CpG dinucleotide content, and several consensus Sp1 and Ap2 binding sequences (Li et al., 1997) .
N-cadherin domains and associated proteins
In this part we will discuss the molecules associated with the extracellular and intracellular part of N-cadherin, their influence on Ncadherin function and the induction of signalling pathways (Fig. 1) .
Although N-cadherin typically forms homotypic homophilic interactions, also heterotypic homophilic and heterophilic interactions have been described. Examples include the interaction between N-cadherin molecules of Sertoli cells and spermatides, and between N-and R-cadherin in transfected L cells and in neurons at certain neural synapses (Shan et al., 2000) .
The fibroblast growth factor receptor (FGFR) is implicated in Ncadherin function. In the nervous system, N-cadherin function is involved in a number of key events that range from the control of axonal growth and guidance to synapse formation to synaptic plasticity (Doherty and Walsh, 1996) . Neurite outgrowth stimulated by N-cadherin is inhibited by a wide variety of agents that block the FGFR function, including the expression of a dominant negative FGFR (Williams et al., 1994) . In addition, N-cadherin can promote contact-dependent survival of ovarian granulosa cells in an FGFRdependent manner (Trolice et al., 1997) . More recently it has been illustrated that both N-cadherin and the FGFR are necessary to increase cell motility and induce metastasising capacity (Suyama et al., 2002) . N-cadherin and the FGFR interact directly: the HAV sequence present in the FGFR associates with the IDPVNGQ sequence present in EC4 of N-cadherin (Williams et al., 2001 ). This motif was already previously described as a candidate for interaction with FGFR, based on sequence homology of the motifs within N-cadherin (INPISGQ in EC1) and R-cadherin (IDPVSGR in EC1) that interact with the HAV region in N-cadherin (Doherty and Walsh, 1996; Williams et al., 2000b) . Peptides used to investigate N-cadherin function were found to have opposite effects on neurite outgrowth: whereas INP (Williams et al., 2000b ) and a cyclic HAV peptide (Williams et al., 2000a) antagonize its function, the cyclic dimeric version of the HAV and the INPISG sequence have an agonistic effect on neurite outgrowth (Williams et al., 2002) . The latter peptides act by binding to and clustering N-cadherin in the cells, thereby activating the N-cadherin/FGFR signalling cascade. After stimulation with FGF 2, invasion of breast carcinoma cells was demonstrated in the same degree as in cells transfected with N-cadherin, suggesting that N-cadherin and FGFR synergize to generate signals that affect the invasive behaviour. As a consequence of N-cadherin binding, internalisation of the FGFR is inhibited. This is causing a sustained cell surface expression of FGFR, leading to a persistent MAPK-ERK (mitogen activated protein kinase-extracellular signal regulated kinase) activation, MMP-9 expression and tumour invasion (Suyama et al., 2002) .
Thus, N-cadherin may be involved in both ligand-dependent and ligand-independent interactions with the FGFR .
Transfection of epithelial cells with N-cadherin influences the morphology and the behaviour of these cells: it induces a "motile phenotype" (Islam et al., 1996; Hazan et al., 1997) . By transfection of chimeras of E-and N-cadherin in squamous epithelial cells, a 69 amino acid portion of EC4 was identified that is necessary for epithelial to mesenchymal transition and an increase in motility by N-cadherin. The motile phenotype induced by N-cadherin is independent of cell-cell adhesion because an antibody, recognizing the 69 amino acid sequence, inhibited cell motility without inhibiting cell-cell aggregation, providing evidence that adhesion and motility can be two separate features (Kim et al., 2000) .
Recently, an S (suppression of movement) -domain (a Cterminal domain: AA699-710 of E-cadherin) was identified in both E-and N-cadherin, though N-cadherin lacked the capacity to suppress motility, presumably because its domain is masked or latent. This inability of N-cadherin to suppress movement required the presence of the modulation-of-movement-domain (M-domain), consisting of the juxtamembrane domain. The authors suggested several ways in which diversity in cadherin function might arise in different cell types. Variations could be expected if cells differ in expression of molecules that interact with the S and M-domain (Fedor-Chaiken et al., 2003) . For example, N-cadherin has no influence on the movement of MDA-MB-435, but the same molecule inhibits the migration of LM8 mouse osteosarcoma cells (Kashima et al., 2003) . So, the effect of cadherins can be cell type specific.
The cytoplasmic part of N-cadherin is complexed with a multitude of molecules, such as the catenins p120 catenin (p120 ctn ), β-catenin and α-catenin, which are possible regulators of cadherin function. p120 ctn binds to the juxtamembrane domain and is a key molecule in the regulation of the adhesive or motile phenotype. When p120 ctn is phosphorylated, its binding to N-cadherin is increased, reducing the adhesive activity of the latter. Cadherin adhesive activity is also subject to regulation by Rho GTPases. Overexpression of p120 ctn in fibroblasts or cadherin-deficient cells causes a branching phenotype, whereas in epithelial cells an increasing lamellipodia formation is observed. In fibroblast, this cytoplasmic p120 ctn inhibits RhoA, resulting in an increase in cell motility and activation of Rac1 and Cdc42. In line with the direct binding of RhoA and p120 ctn in Drosophila (Magie et al., 2002) , one hypothesis says that a direct interaction of p120 ctn with RhoA keeps RhoA in the inactive GDP state. According to another hypothesis the association of p120 ctn with vav2, a Rho-GEF (guanine nucleotide exchange factor) explains the activation of Rac1 and Cdc42 (Anastasiadis et al., 2001 ).
Fer (fes -related protein; fes: feline sarcoma), a nonreceptor tyrosine kinase, interacts via its coiled-coil domain with the coiledcoil domain of p120 ctn . Fer is implicated in the regulation of adherens junctions and focal adhesions. Trojan peptides, recognizing the juxtamembrane domain of N-cadherin, caused Fer to dissociate from N-cadherin, rendering Fer available for complex formation with FAK (Arregui et al., 2000) . This correlated with disruption of focal adhesion and reduced tyrosine phosphorylation of the docking protein p130Cas. These observations indicate that Fer has a role in the regulation of cell adhesion and migration through effects on both adherens junctions and focal adhesions (Greer, 2002) . Fer and Fyn kinase phosphorylate Tyrosine 142 of β-catenin, and this (unphosphorylated) tyrosine is necessary for the association of β-catenin with α-catenin. In contrast, phosphorylation of tyrosine residues of p120 ctn increases the binding of the Fer/Fyn-p120ctn complex to cadherin (Piedra et al., 2003) . P120 ctn not only modulates the function of cadherins but is also important in the trafficking and maturation of the cadherin-catenin complex. Wahl et al., have shown that p120 ctn readily associates to the cytoplasmic part of N-cadherin in the endoplasmatic reticulum (ER). Later on, the cytoplasmic part is phosphorylated, leading to additional binding of β-and α-catenin. The proregion is then removed by furin protease and the complex is transported to the plasma membrane (Wahl et al., 2003) . N-cadherin trafficking is mediated by a microtubular kinesin-driven mechanism (Mary et al., 2002) and recent papers elucidated that p120 ctn is the link with the microtubule network by direct association of p120 ctn with kinesin Yanagisawa et al., 2003) . Presenilin 1 (PS1), playing a role in the pathogenesis of early onset familial Alzheimer disease, also binds to the juxtamembrane domain and modulates the adhesive capacity. When dominant negative PS1 is expressed, cell-cell contacts are suppressed, and N-cadherin is localised perinuclearly at the ER and Golgi apparatus. So, PS1 is essential for the trafficking of N-cadherin to the plasma membrane (Uemura et al., 2003) .
Another point where the cadherin/catenin complex can be regulated is at its interaction with β-catenin, which is responsible for association with α-catenin and hence for linking the complete complex to the actin network. The interaction of β-catenin with Ncadherin is regulated by multiple proteins . The proteoglycan neurocan can inhibit N-cadherin-and β1-integrinmediated adhesion and neurite outgrowth. Neurocan interaction with its receptor GalNAcPTase leads to tyrosine hyperphosphorylation of β-catenin and uncoupling of β-catenin from the complex (Lilien et al., 1999; .
Hyperphosphorylation of β-catenin has consistently been correlated with loss of adhesive function. The nonreceptor protein tyrosine phosphatase PTP1B regulates the phosphorylation of β-catenin (Balsamo et al., 1998) . PTP1B needs to be phosphorylated on tyrosine-152 for its association with N-cadherin (Rhee et al., 2001 ). PTP1B binds to the cytoplasmic part, specifically to the amino acids 872-891 of N-cadherin, and this domain partially overlaps with the β-catenin binding domain. Despite the partial overlap of binding domains, β-catenin and PTP1B do not compete with each other for binding . The interaction of Ncadherin with PTP1B is essential for its association with β-catenin, its stable expression at the cell surface, and consequently, its function. Gα12/13, a Gα subunit of the heterodimeric G proteins, associates with the cytoplasmic part of N-cadherin, overlapping the binding site of PTP1B, so binding of Gα may displace PTP1B and vice versa (Kaplan et al., 2001 ). The phosphatase PTPµ directly interacts with the carboxy-terminal domain of the cadherins, potentially dephosphorylating these. The absence of PTPµ is correlated with increased phosphorylation of the cadherin itself, but not of β-catenin (Brady-Kalnay et al., 1998). On its turn, increased tyrosine phosphorylation of N-cadherin has been associated with increased turnover of N-cadherin, releasing a 90 kD extracellular fragment (Lee et al., 1997) . N-cadherin phosphorylated by Src on tyrosine 851 and 883, associates with the SH2 domain of the adapter protein Shc (Xu and Carpenter, 1999) , opening the door to different signalling pathways.
N-cadherin function and signalling
N-cadherin promotes survival in melanoma and prostate carcinoma cells. N-cadherin ligation recruits phosphatidylinositol 3-kinase (PI3K) which activates Akt, resulting in inactivation of the pro-apoptotic molecule Bad (Bcl2 antagonist of cell death, Bcl2 is the acronym for B cell lymphoma) (Li et al., 2001; Tran et al., 2002) .
However, N-cadherin can also have an inhibitory effect on cell proliferation. Overexpression of N-cadherin in cells suppresses cell proliferation by prolonging the G2/M phase and inducing β-catenin dependent expression of p21 (inhibitor of cyclin dependent kinase, cdk) which inhibit Cdc2 activity . P27, another cdk inhibitor is involved in N-cadherin mediated contact inhibition of cell growth and cell cycle arrest in the G1 phase (Levenberg et al., 1999 epithelial phenotype in vivo but become rapidly fibroblastic and invasive when explanted in vitro. In these conditions they undergo a switch from E-to N-cadherin expression. Such a switch was already seen in the epiblast cells of the chick embryo when the cells where treated with hepatocyte growth factor (HGF) (Deluca et al., 1999) . We found indications for an autocrine HGF/c-Met loop stimulating RPE cell invasion via focal adhesion kinase (FAK). Ncadherin activates FAK in invasive RPE cells (Van Aken et al., 2003) .
In order to mimic and control the formation of cadherin mediated cell-cell contacts, N-cad-Fc chimera, comprising the N-cadherin ectodomain linked to an IgG Fc fragment, have been used. These chimera form dimers by inter-chain disulfide bridges of the Fc domains. Chimera-loaded beads bound specifically to various cells expressing N-cadherin, inducing a rapid recruitment of cadherin/catenin complexes, followed by a strong anchorage of actin filaments, leading to cytoskeletal reorganisation and activation of intracellular signalling pathways (Lambert et al., 2000) .
Rac1 is required for the anchoring of the cadherin/catenin complex to the actin filaments in the myogenic C2 cells (Lambert et al., 2002) . Further studies demonstrated that for the formation of lamellipodia a p120 ctn -PI3K-Rac1 pathway is triggered, while for the organisation of the cadherin complex and the actin cytoskeleton only p120 ctn and Rac1 are needed (Gavard et al., 2004) . In addition, N-cadherin also controls crucial steps in myogenic differentiation, and addition of N-cad-Fc beads triggered myogenesis in isolated myoblasts. Here, inactivation of Rac1 and Cdc42 was observed, while RhoA was activated. The RhoA GTPase activity is important for myogenic differentiation since it controls the expression and the activity of the transcription factor SRF (serum response factor) which binds to motifs present in the promoter of muscle-specific genes. As a result the promoter of muscle-determining factor MyoD is stimulated by N-cadherin-dependent contact formation (Charasse et al., 2002) . A balance between Rac1-Cdc42 and RhoA activity determines the cellular phenotype and biological behaviour of various cell systems: actin cytoskeleton organisation, formation of focal adhesions, neurite extension and myogenesis. In fibroblasts the activation of RhoA leads to assembly of stress fibers and focal contacts, which mediate adhesion to ECM. Activation of Rac1 and Cdc42, however, results in the formation of filopodia and lamellipodia. In mouse fibroblasts, Rac1 signalling is able to antagonize Rho activity. Activation of Rac1 by the GEF Tiam1 in these cells induces an epithelial-like morphology with functional cadherin-based adhesion and inhibition of migration (Sander et al., 1999; Yap and Kovacs, 2003) .
Full length N-cadherin and its 90 kD N-terminal fragment have been shown to promote cell-matrix adhesion and neurite outgrowth when presented as a substratum (Paradies and Grunwald, 1993; Bixby et al., 1994) . Soluble N-cad-Fc can also stimulate FGFR dependent neurite outgrowth (Utton et al., 2001) . N-cadherin is expressed in human endothelial cells, but its function in angiogenesis is not fully elucidated. Literature data demonstrated that N-cadherin is expressed during early neuroectoderm vascularization where it probably establishes interactions between neuroectoderm and endothelium, followed by a downregulation of N-cadherin in endothelia when the cells differentiate to a blood-retina and blood-brain barrier (Gerhardt et al., 1999) . N-cadherin has also been indicated as an angiogenic factor in nonsmall-cell lung cancer because biopsies positive for N-cadherin were hypervascular (Nakashima et al., 2003) . In our laboratory we could find that plasmin cleaved a 90 kD ectodomain fragment from N-cadherin, coined soluble N-cadherin. Soluble N-cadherin induced angiogenesis in the chick chorioallantoic membrane and the rabbit cornea. The 10-mer HAV peptide (LRAHAVDING) had the same pro-angiogenic effect as soluble N-cadherin (our unpublished data).
N-cadherin up-and downregulation
The N-cadherin/catenin functions are influenced by multiple intracellular and extracellular factors (Table 1 ). We will discuss a few factors more into detail. The upregulation of N-cadherin at the transcription level has been explored. In Drosophila development the transcription factor twist initiates DN-cadherin expression during early mesoderm formation. Another transcription factor, snail, is required for an increase in the level of N-cadherin (Oda et al., 1998) . In biopsies of gastric carcinoma, a correlation was demonstrated between the expression of N-cadherin and twist (Rosivatz et al., 2002) . Growth factors as EGF and HGF are able to induce a switch from E-to N-cadherin. An example is found in breast carcinoma cells co-expressing E-and N-cadherin. When treated with EGF they undergo epithelial-mesenchymal transitionlike changes, including upregulation of vimentin, downregulation of E-cadherin and upregulation of N-cadherin (Ackland et al., 2003) . P120 ctn is an important regulator of the turnover of cadherins. Upon p120 ctn knockdown with siRNA (small interfering RNA), the cadherins are rapidly degraded, probably via ubiquitination (Davis et al., 2003) . Also, proteases like MMP (Paradies and Grunwald, 1993) , caspase-3 (Hunter et al., 2001 ) and presenilin (Marambaud et al., 2003) Balsamo et al., 1991 Balsamo et al., 1995 Guo et al., 2003 Abbreviations used: GATA-4, zinc finger transcription factor recognizes the consensus motif (A/T)GATA(A/G); SOX9, DNA binding SRY box found in SOX family member; Pax6, paired box protein 6; HOXD3, Homeobox D3; HGF, hepatocyte growth factor; EGF, epidermal growth factor; IL-6, interleukin 6; siRNA, small interfering RNA; TF, transcription factor; PKC, protein kinase C; CBP, CREB binding protein; CREB, cyclic AMP response element binding protein.
residual transmembrane/ intracellular part is not clear. Only for the intracellular peptide fragment of N-cadherin, produced after PS1 cleavage, a role is described. It forms a complex with transcriptional coactivator CBP (CREB binding protein) in the cytoplasm and promotes the proteasomal degradation of CBP, via the ubiquitinproteasome pathway. N-cadherin has an important role during embryogenesis. Thalidomide, a drug that causes teratogenicity, affects mostly organs originating from neural crest cells. Thalidomide was found to bind at the N-terminal domain of N-cadherin, mimicking a tryptophan residue which is critical for its homodimerization, and thus functionally inhibiting homodimerisation (Thiele et al., 2000) . In axon trajectories, the Robo transmembrane receptor forms a complex with N-cadherin. After activation with Slit, a complex between Robo, Abl and N-cadherin is formed, followed by tyrosine phosphorylation of β-catenin and resulting in loss of the critical N-cadherin-actin connection (Rhee et al., 2002) .
N-cadherin expression from embryo to adult
Members of the cadherin superfamily have distinct expression patterns during embryonic development and in the adult. Changes in cadherin expression are often associated with changes in cellular morphology and tissue architecture. During gastrulation, E-cadherin is downregulated in the primitive streak as cells undergo an epithelial-mesenchymal transition and concomitantly express N-cadherin in the mesoderm (Hatta and Takeichi, 1986 ). This expression of N-cadherin is initiated by the transcription factor twist in Drosophila (Oda et al., 1998) . During neurulation, a similar change in expression occurs in the developing neuroepithelium. Different groups analysed the role of N-cadherin in embryogenesis by using knockouts or an artifical system of cytodifferentiation, in which either teratomas or cultured embryoid bodies from genetically manipulated embryonic stem (ES) cells are generated and analysed. When N-cadherin was constitutively expressed in the Ecadherin negative ES cells, the resulting teratomas formed neuroepithelia and cartilage (Larue et al., 1996) . N-cadherin knockout mice die at day 10 of gestation. The embryos display major heart defects and malformed neural tubes and somites (Radice et al., 1997) . However, all tissues expected to be formed at this stage are apparently present and seem to be normally differentiated. Reexpression of N-cadherin using muscle-specific promoters (α-or β-myosin heavy chain) partially rescues N-cadherin null embryos. These embryos exhibit an increased number of somites, branchial arches and the presence of forelimb buds, however, brain development is still impaired (Luo et al., 2001) . N-cadherin is implicated in several aspects of cardiac development including sorting out of the precardiac mesoderm, establishment of left-right asymmetry, cardiac looping morphogenesis and trabeculation of the myocardial wall. N-cadherin is one of the earliest proteins to be asymmetrically expressed in the chicken embryo and its activity is required during gastrulation for a proper establisment of the left-right axis (Garcia-Castro et al., 2000) . In the early embryo N-cadherin is found in the mesoderm and the notochord, while in the late embryo it is present in neural tissue, lens and some other epithelial tissues, cardiac and skeletal muscles, nephric primordial, some mesenchymal tissue, mesothelium and primordial germ cells (Hatta et al., 1987; Takeichi, 1988) . N-cadherin is expressed in early hematopoietic cells (CD34 + CD19 + ) and is involved in the development and retention of early hematopoietic cells in the bone marrow (Puch et al., 2001) .
Cartilage formation in the developing vertebrate embryonic limb consists of highly coordinated and orchestrated series of events involving the commitment, condensation and chondrogenic differentiation of mesenchymal cells and the production of cartilaginous matrix. Here, N-cadherin has a role in the cellular condensation (Tuan, 2003) , being a direct target of SOX9, a transcription factor that is essential for chondrocyte differentiation and cartilage formation (Panda et al.,2001) . Misexpression of wnt7a (wingless/int, a chondro-inhibitor in vitro) in mesenchymal chondrogenic cultures directly led to prolonged expression of N-cadherin, stabilisation of N-cadherin mediated cell-cell adhesion and eventual inhibition of chondrogenesis (Tufan and Tuan, 2001; Tufan et al., 2002) . Ncadherin mRNA levels increase during osteogenic and myogenic differentiation and decrease during adipogenic differentiation. Ncadherin is expressed in all stages of osteoblast bone formation: mRNA levels for example increase at the stages of nodule formation and mineralisation, and in vitro N-cadherin levels increase concomitantly with osteoblast differentiation (Ferrari et al., 2000) .
A lot of factors regulate the expression of N-cadherin in osteoblasts: BMP-2, FGF-2 and phorbol ester increase the level of Ncadherin in a PKC-dependent way, while TNFα and IL-1 are responsible for a decrease in expression. However, N-cadherin expression is decreased in primary and metastatic osteosarcoma (see also below) (Marie, 2002) . N-cadherin plays also an important role in skeletal muscle differentiation. Cells with the potential to undergo skeletal myogenesis are present in the epiblast layer. All cells express the skeletal muscle-specific transcription factor MyoD but only the epiblast cells that express N-cadherin but not E-cadherin will differentiate into skeletal muscle (George-Weinstein et al., 1997).
So, N-cadherin is involved in myoblast migration and homing as well as in muscle differentiation (Brand-Saberi et al., 1996) .
Migratory cells play an important role in embryonic development and disease. A migratory cell population known as neural crest can be defined as a pluripotent population of cells that arise from the dorsal part of the neural tube during or just before closure. After an epithelial-mesenchymal transition (EMT), they migrate over long distances along distinct pathways to many different regions of the embryo and contribute to a diverse array of tissues and cell types, such as the peripheral nervous system, melanocytes, some endocrine cells, craniofacial cartilage and bone. The transcription factor Slug is involved in both the formation of the neural crest precursors and in neural crest migration. Slug downregulates cadherins, leading to a loss of cell-cell contacts and allowing the cells to migrate. Indeed, when neural crest cells are still associated with the neural tube, they express N-cadherin but once they start migrating N-cadherin is downregulated. At the end of the dorso-ventral migration Ncadherin is re-expressed in aggregating cells, just before the formation of the dorsal root and sympathic ganglia. After the dorso-lateral migration only the dermal melanocytes express Ncadherin and establish contacts with the fibroblasts in the dermis (Nieto, 2001; Pla et al., 2001) .
As is evident from the above, N-cadherin is expressed at different time points and tissues in the embryo. In the adult, Ncadherin is restricted to neural tissue, retina, endothelial cells, fibroblasts, osteoblasts, mesothelium, myocytes, limb cartilage, oocytes, spermatids and Sertoli cells. Abbreviations used: '+', expression of N-cadherin; '-', no expression of N-cadherin; up, upregulation; down, downregulation; AFP, alpha-foetoprotein; ATL, adult T-cell leukemia; T cell leukemia, human thymus derived cell line.
N-cadherin and cancer
The process of EMT not only occurs under physiological conditions during normal embryonic development, it also takes place in pathological situations, such as the acquisition of an invasive phenotype in tumour cell lines of epithelial origin. This goes together with the first steps of the metastatic process. The EMT associated with tumour progression frequently involves downregulation of E-cadherin expression and the acquisition of migratory properties. Snail is a strong and direct repressor of Ecadherin (Cano et al., 2000) , and influencing the levels of Ncadherin expression, a pro-migratory factor. Indeed, in a number of human cancer types which have lost E-cadherin, de novo expression of N-cadherin is observed .
The cadherins have been investigated in different areas of tumour biology. In early neoplasia cadherins play a role in the transformation of cells to an abnormal proliferative phenotype. E and N-cadherin are normally involved in inducing cell cycle arrest. However, N-cadherin also promotes survival in normal granulosa cells (Makrigiannakis et al., 1999) and in melanoma cells (Tran et al., 2002) by distinct mechanisms. In epithelial carcinomas Ecadherin is downregulated in most cases, sometimes accompanied by the upregulation of another cadherin, for example Ncadherin, P-cadherin or cadherin -11. Here, we will focus on the expression of N-cadherin in cancer. We reviewed the literature and present an overview of N-cadherin expression in cancer cells and looked whether this was also the case in their embryonic and adult normal counterparts (Tabled 2). The table is divided into 4 groups: in the first one (including breast, prostate, bladder, thyroid and squamous cell carcinoma) N-cadherin is 'DE NOVO EXPRESSED' (Table 2 ) in the cancer cell and N-cadherin is never expressed in the corresponding precursor or adult normal cells. In 1996 the aberrant expression of N-cadherin in squamous cell carcinoma was described. The inappropriate expression of N-cadherin in these cells correlated with a scattered fibroblastic phenotype along with decreased expression of E-and P-cadherin. Transfection with antisense N-cadherin resulted in reversion to a normal appearing squamous epithelial cell morphology, and increased expression of E-and P-cadherin. In addition, transfection of a normal squamous epithelial cell line with N-cadherin induced the scattered fibroblastic phenotype (Islam et al., 1996) . Aberrant N-cadherin expression was also found in breast carcinoma cells and biopsies. Breast carcinoma cells expressing N-cadherin are more motile and invasive (Hazan et al., 1997 and . In biopsies N-cadherin was mostly found in invasive carcinoma, but no correlation could be found with grade (Paredes et al., 2002) or patient survival (Peralta Soler et al., 1999) . De novo expression of N-cadherin was found most frequently in prostate carcinoma: in one series, 60% was positive in carcinomas with a Gleason score above 7 . In vitro studies show that the expression of N-cadherin mediates an epithelial-mesenchymal transformation, possibly improving the physical interaction with the surrounding stromal fibroblasts and facilitating metastasis (Tran et al., 1999) .
In the group 'RE-EXPRESSION' (Table 2) we classified tumours that had embryonic precursor cells expressing N-cadherin. One of the best examples are melanoma cells: melanocytes are derived from neural crest cells, which are N-cadherin positive before they start migrating. N-cadherin was found back in metastasising melanomas (Matsuyoshi et al., 1997; Sanders et al., 1999) . In gastric carcinoma N-cadherin was found in all α-foetoprotein producing tumours (Yanagimoto et al., 2001 ) and a correlation was found between the expression of twist and N-cadherin expression (Rosivatz et al., 2002) . During early development N-cadherin is found in some basal granulated epithelial cells of the stomach, duodenum and jejunum (Gaidar et al., 1998) . Another example is the expression of N-cadherin in T-cell leukemia cell lines. Here, Ncadherin is functionally active because it stimulates the co-aggregation and adhesion with mesenchymal cells, which presumably facilitates invasion in mesenchymal tissues of the skin and the central nervous system (Kawamura-Kodama et al., 1999) .
A third group, 'UPREGULATION' ( Table 2 ), shows that cells already expressing N-cadherin in embryonic and adult stages can still increase their levels of expression in neoplastic stages. One example is pleural mesothelioma, where a high and homogeneous expression is characteristic Ordónez, 2003) .
In the last group we collected cancers where N-cadherin levels remain unaltered or are 'DOWNREGULATED' (Table 2 ). In osteosarcoma, N-cadherin inhibits cell migration and the formation of metastasis (Kashima et al., 1999 and . In gliobastoma no differences were found in N-cadherin expression but at the time of recurrence, decreased N-cadherin expression correlates with dissemination in malignant astrocytic tumours (Asano et al., 2000) . In ovarian carcinoma, N-cadherin is expressed in the different stages but one report mentioned that mucinous cystadenomas were Ncadherin negative . Recently it was shown that probably P-cadherin is the important aberrantly expressed cadherin in ovarian cancer (Patel et al., 2003) .
In summary, multiple in vitro and in vivo studies showed that aberrant N-cadherin (re-) expression correlates in most cases with a morphological change towards a more fibroblastic phenotype, with cells becoming more motile, invasive and metastatic. There are, however, invasive tumours where N-cadherin is downregulated and where it may play the role of a tumour suppressor molecule. Nowadays, loss of immunohistochemical E-cadherin expression is sometimes used in surgical pathology to characterize gastric and breast carcinomas. It may be worthwhile to explore also the cases where N-cadherin is aberrantly expressed, and challenge N-cadherin as a candidate prognostic marker. Another ongoing project in our laboratory is the use of circulating soluble Ncadherin, the 90 kD fragment that is released after MMP cleavage, as a potential tumour marker of invasion. Soluble E-cadherin, a 80 kD ectodomain fragment, in the serum or urine of patients with urothelial carcinoma (Griffiths et al., 1996) , ovarian carcinoma (Gadducci et al., 1999) and gastric carcinoma (Gofuku et al., 1998) has already been launched as a circulating tumour marker. Yet, we believe that soluble N-cadherin has better chances as a potential circulating tumour marker than soluble E-cadherin, because in general N-cadherin expression is upregulated in invasive tumours.
Conclusion
N-cadherin is associated with a lot of molecules that regulate its function. It is involved in a lot of processes like cell-cell adhesion, differentiation, embryogenesis, migration, invasion and signal transduction. In embryogenesis, during gastrulation, cells undergo an epithelial-mesenchymal transition leading to the expression of Ncadherin and the downregulation of E-cadherin in the mesoderm. This switch is regulated by multiple growth and transcription factors. A similar situation appears in carcinomas where loss of Ecadherin is correlated with an upregulation of N-cadherin. The aberrant expression (de novo or re-expression) of N-cadherin attributes a more fibroblastic phenotype to the cancer cells, and they become more motile and invasive. One of the transcription factors responsible for upregulation is twist. Further research on other possible factors that affect the N-cadherin switch, on the signalling pathways initiated in N-cadherin mediated invasion and on the perspective of N-cadherin as a potential marker of invasion is needed.
